The University of Oxford conducted a study recently in collaboration with a handful of other UK research centers all supported by the UK Coronavirus Immunology Consortium leading to what very well could be one of the most compelling immune response studies to date centering on the Pfizer-BioNTech COVID-19 vaccine. The study team found that if the duration between the first and second jab is delayed—leading to a longer gap between doses—that the corresponding antibody and T cell immune responses grow stronger in effect.
Known as the Protective Immunity from T Cells to COVID-19 in Health Workers study (PITCH), the study team, which also included the Universities of Birmingham, Newcastle, Liverpool, and Sheffield, and was supported by the UK Coronavirus Immunology Consortium, found T cell levels are well-maintained and antibody levels are higher following a longer interval between the first and second dose of the Pfizer COVID-19 vaccine, even if there is a drop in antibody levels between doses.
The University of Birmingham issued a press release declaring that importantly, studies from around the world reveal that both the short and long dosing schedules lead to st...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).